Refractory hematuria post actinic cystitis. Role of potassium alumen as treatment - Case Report

Main Article Content

João Ernesto Aldred Pinto Filho*
Pedro Henrique Ejje Kailly
Ruston da Matta Louback Filho
Juan Miguel Renteria
Antonio Claudio
Ahouagi Cunha

Abstract

Actinic cystitis hematuria is a frequent complication after pelvic radiotherapy, present in approximately 5% of patients exposed to this therapy. The management of these cases seems to be a challenge for today’s urologists. In this article, we present the case of a 73- year-old man diagnosed with actinic cystitis after pelvic radiotherapy and admitted to our service with a clinical picture of refractory macroscopic hematuria. During admission, the patient underwent multiple procedures and blood transfusions, without success in controlling hematuria. After a review of the literature, we chose to use Potassium Alum in the patient’s treatment. Under general anesthesia, we performed a cystoscopy with the evacuation of clots and subsequently infused a 1% solution of potassium alum into the bladder at a rate of 200 ml/h for 25 hours. Less than 24 hours after Alum infusion, there were no more clinical signs of hematuria, which remained until hospital discharge. After 6 months of treatment, the patient did not present another episode of hematuria.

Downloads

Download data is not yet available.

Article Details

Pinto Filho, J. E. A., Ejje Kailly, P. H., Louback Filho, R. da M., Renteria, J. M., Claudio, A., & Cunha, A. (2022). Refractory hematuria post actinic cystitis. Role of potassium alumen as treatment - Case Report. Global Journal of Medical and Clinical Case Reports, 9(2), 029–031. https://doi.org/10.17352/2455-5282.000153
Case Reports

Copyright (c) 2022 Aldred Pinto Filho JE, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.

We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.

Peertechz accomplice with- [CC BY 4.0]

Explanation

'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.

With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:

License Name

Permission to read and download

Permission to display in a repository

Permission to translate

Commercial uses of manuscript

CC BY 4.0

Yes

Yes

Yes

Yes

The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.

Rastinehad AR, Kavoussi LR, Noble MJ. Hemorrhagic cystitis. AUA Update Series. 2007.

Smit SG, Heyns CF. Management of radiation cystitis. Nat Rev Urol. 2010 Apr;7(4):206-14. doi: 10.1038/nrurol.2010.23. Epub 2010 Mar 9. PMID: 20212517.

Shepherd JD, Pringle LE, Barnett MJ, Klingemann HG, Reece DE, Phillips GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol. 1991 Nov;9(11):2016-20. doi: 10.1200/JCO.1991.9.11.2016. PMID: 1941060.

O'Reilly KJ, Hampson NB, Corman JM. Hyperbaric oxygen in urology. AUA Update Series. 2002.

Del Pizzo JJ, Chew BH, Jacobs SC, Sklar GN. Treatment of radiation induced hemorrhagic cystitis with hyperbaric oxygen: long-term followup. J Urol. 1998 Sep;160(3 Pt 1):731-3. doi: 10.1097/00005392-199809010-00026. PMID: 9720533.

Choong SK, Walkden M, Kirby R. The management of intractable haematuria. BJU Int. 2000 Dec;86(9):951-9. doi: 10.1046/j.1464-410x.2000.00900.x. PMID: 11119085.

Westerman ME, Boorjian SA, Linder BJ. Safety and efficacy of intravesical alum for intractable hemorrhagic cystitis: A contemporary evaluation. Int Braz J Urol. 2016 Nov-Dec;42(6):1144-1149. doi: 10.1590/S1677-5538.IBJU.2015.0588. PMID: 27509371; PMCID: PMC5117970.